Chest
Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only ArticlesAntiplatelet Drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Section snippets
Aspirin
Aspirin is the most widely studied antiplatelet drug. On the basis of > 100 randomized trials in high-risk patients, aspirin reduces vascular death by ∼15% and nonfatal vascular events by ∼30%.9, 10
Mechanism of Action
Dipyridamole is a pyrimidopyrimidine derivative with vasodilator and antiplatelet properties. The mechanism of action of dipyridamole as an antiplatelet agent is controversial.148 Both inhibition of cyclic nucleotide phosphodiesterase (the enzyme that degrades cyclic adenosine monophosphate [AMP] to 5′-AMP, resulting in the intraplatelet accumulation of cyclic AMP, an inhibitor of platelet aggregation) and blockade of the uptake of adenosine (which binds to A2 receptors, stimulates platelet
Mechanism of Action
Cilostazol is a 2-oxoquinolone derivative that is reported to have vasodilatory and antiplatelet properties as well as antiproliferative effects, reducing smooth muscle cell proliferation and neointimal hyperplasia after endothelial injury. Cilostazol is a common cause of GI side effects, and headache occurs in up to one-fourth of patients within the first 2 weeks of starting treatment. Cilostazol is contraindicated in patients with heart failure because of the potential to trigger ventricular
Thienopyridines
Ticlopidine, clopidogrel, and prasugrel represent three generations of oral thienopyridines that selectively inhibit ADP-induced platelet aggregation. The first-generation agent ticlopidine was limited by bone marrow toxicity and has largely been replaced by clopidogrel, which has become established as standard therapy across the spectrum of patients with ACS and in those undergoing percutaneous coronary intervention (PCI). However, clopidogrel also has limitations, including variable
Glycoprotein IIb/IIIa Antagonists
The pharmacologic characteristics of the three approved IV glycoprotein IIb/IIIa (GpIIb-IIIa) inhibitors abciximab, tirofiban, and eptifibatide are summarized in Table 7.
Conclusion
Antiplatelet therapies are effective for prevention of platelet-rich arterial thrombi that form under high-shear conditions. Antiplatelet therapies are also effective for the prevention of fibrin-rich thrombi that form under low-shear conditions, such as VTE and left atrial appendage thrombi that form in patients with atrial fibrillation, but for these indications, antiplatelet drugs are less effective than anticoagulants. The efficacy of antiplatelet drugs for thrombosis prevention is
Acknowledgments
Author contributions: As Topic Editor, Dr Eikelboom oversaw the development of this article, including any analysis and subsequent development of the information contained herein.
Dr Eikelboom: contributed as Topic Editor.
Dr Hirsh: contributed as a panelist.
Dr Spencer: contributed as a panelist.
Dr Baglin: contributed as a panelist.
Dr Weitz: contributed as a panelist.
Financial/nonfinancial disclosures: In summary, the authors have reported to CHEST the following conflicts of interest: Dr
References (267)
- et al.
Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Chest
(2004) - et al.
Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest
(2008) - et al.
Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2
J Biol Chem
(1996) - et al.
Possible significance of small numbers of functional platelets in a population of aspirin-treated platelets in vitro and in vivo
Thromb Res
(1980) Effects of salicylates on human platelets
Lancet
(1968)- et al.
Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs
Blood
(1987) Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease
Lancet
(1990)- et al.
Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris
Lancet
(1992) Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events
Lancet
(1991)- et al.
European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke
J Neurol Sci
(1996)
Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial. ASA and Carotid Endarterectomy (ACE) Trial Collaborators
Lancet
Improved aortocoronary bypass patency by low-dose aspirin (100 mg daily). Effects on platelet aggregation and thromboxane formation
Lancet
Aspirin and prophylaxis of thromboembolic complications in patients with substitute heart valves
J Thorac Cardiovasc Surg
Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement: danger of aspirin compared with dipyridamole
Am J Cardiol
Prevention of arterial thromboembolism with acetylsalicylic acid. A controlled clinical study in patients with aortic ball valves
Am Heart J
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke
Lancet
Aspirin inhibits platelet function independent of the acetylation of cyclo-oxygenase
Thromb Res
Pharmacology of platelet inhibitors
J Am Coll Cardiol
Antiplatelet drugs and generation of thrombin in clotting blood
Blood
Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects
J Am Coll Cardiol
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial
Lancet
Effect of aspirin on mortality in primary prevention of cardiovascular disease
Am J Med
Primary and secondary prevention of cardiovascular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines
Chest
Platelet activation and atherothrombosis
N Engl J Med
Mechanisms of platelet activation
Regulation of megakaryopoiesis
Determinants of platelet number and regulation of thrombopoiesis
Hematology (Am Soc Hematol Educ Program)
Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets
Proc Natl Acad Sci U S A
Activated platelets mediate inflammatory signaling by regulated interleukin 1beta synthesis
J Cell Biol
Low-dose aspirin for the prevention of atherothrombosis
N Engl J Med
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients
BMJ
Inhibition of platelet prostaglandin synthetase by oral aspirin
J Clin Invest
Arachidonate metabolism in vascular disorders
J Clin Invest
The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein
J Clin Invest
Acetylation of prostaglandin synthase by aspirin
Proc Natl Acad Sci U S A
The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase
Nat Struct Biol
Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2
Proc Natl Acad Sci U S A
Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin
N Engl J Med
Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress
Proc Natl Acad Sci U S A
Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man
J Clin Invest
Altered pain perception and inflammatory response in mice lacking prostacyclin receptor
Nature
Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials
BMJ
Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities
J Clin Invest
Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase
N Engl J Med
Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers
Stroke
Transdermal modification of platelet function: an aspirin patch system results in marked suppression of platelet cyclooxygenase
J Pharmacol Exp Ther
Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework
Lancet
Clinical pharmacology of platelet cyclooxygenase inhibition
Circulation
Sensitivity of fatty acid cyclooxygenase from human aorta to acetylation by aspirin
Proc Natl Acad Sci U S A
The role of prostaglandins in platelet function
Semin Hematol
Cited by (346)
Risk of venous thromboembolism in autoimmune diseases: A comprehensive review
2023, Autoimmunity ReviewsMortality and morbidity following initiation of anticoagulant or antiplatelet treatment for blunt cerebrovascular injury
2023, Journal of Vascular SurgeryResponse of human blood platelets to preparations from leaves of Paulownia Clon in Vitro 112
2023, Biomedicine and Pharmacotherapy
Funding/Support: The Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines received support from the National Heart, Lung, and Blood Institute [R13 HL104758] and Bayer Schering Pharma AG. Support in the form of educational grants was also provided by Bristol-Myers Squibb; Pfizer, Inc; Canyon Pharmaceuticals; and sanofi-aventis US.
Disclaimer: American College of Chest Physician guidelines are intended for general information only, are not medical advice, and do not replace professional medical care and physician advice, which always should be sought for any medical condition. The complete disclaimer for this guideline can be accessed at http://chestjournal.chestpubs.org/content/141/2_suppl/1S.
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (http://www.chestpubs.org/site/misc/reprints.xhtml).